e.l.f. Beauty: Portfolio Growth Continues, But Core Pressures Persist

What happened

e.l.f. Beauty reported its 29th consecutive quarter of net sales growth in Q4 2026, with all five brands—including standout performances from rhode and Naturium—supporting the company's transformation into a diversified beauty player. However, the DeepValue report flags that this growth is increasingly acquisition-driven, with FY26 guidance implying only ~3-4% organic growth (ex-Rhode) and flat EBITDA despite the Rhode contribution. The core business faces headwinds from elevated China tariffs (~60% in FY26 vs 25% prior), which have compressed gross margins and forced broad price increases, masking underlying volume trends. Management's deliberate trade-off of near-term earnings for marketing spend and tariff mitigation has led to a ~40% stock drawdown from highs, yet the stock still trades at ~64x trailing EPS and ~28x EV/EBITDA. While the portfolio expansion narrative is intact, the risk-reward remains unfavorable given the high valuation prices in a rapid return to mid-teens organic growth and 70%+ gross margins—an outcome that the filing-level data suggests is far from assured.

Implication

In the near term, the stock may find support from continued strength at rhode and Naturium, but the core e.l.f. brand's reliance on tariff-heavy pricing and elevated marketing spend leaves limited margin for error. Over 6–12 months, any disappointment on organic growth or margin recovery could trigger further multiple compression toward the low-20s EV/EBITDA, implying downside to the mid-$60s. The DeepValue report's base case of ~$85 and bear case of ~$55 highlight that risk outweighs reward at current levels. Investors should wait for a better entry near ~$65 or until FY27 guidance confirms a sustainable re-acceleration in ex-Rhode growth and gross margin stabilization above 69%. Trimming positions on strength remains prudent given the asymmetry.

Thesis delta

The Seeking Alpha article's bullish framing around portfolio momentum and consecutive growth quarters does not alter the DeepValue report's central concern: that the underlying organic and margin trajectory is structurally lower than the market prices in. The thesis remains that the current valuation—at ~64x trailing EPS—prices in a quick return to mid-teens growth and 70%+ gross margins, which the filing-level data shows is unlikely without a material easing of tariffs or a sustained volume re-acceleration. Therefore, the risk-reward remains skewed to the downside, reinforcing the 'POTENTIAL SELL' rating and the preference for waiting for a lower entry or clearer evidence of organic re-acceleration.